Circulating S100A8 and S100A9 protein levels in plasma of patients with acquired aplastic anemia and myelodysplastic syndromes

Cytokine. 2019 Jan;113:462-465. doi: 10.1016/j.cyto.2018.06.025. Epub 2018 Jun 27.

Abstract

The alarmin family members S100A8 and S100A9 are acute phase inflammation proteins, but they also have been proposed as biomarkers in many malignant and non-malignant diseases. In this study, circulating S100A8 and S100A9 homodimers and S100A8/A9 heterodimers in plasma were systematically investigated by ELISA in aplastic anemia (AA) and myelodysplastic syndromes (MDS). Plasma was obtained from 58 severe AA (SAA) and 30 MDS patients, and from 47 age- and sex-matched healthy donors. In 40 out of the 58 AA subjects, S100A protein levels were measured before and 6 months after immunosuppressive therapy (IST). No differences were observed in AA patients at diagnosis compared to healthy controls for circulating S100A homodimers and heterodimers. After therapy, SAA-responders showed significantly increased circulating S100A8. Non-responding patients had significantly higher levels of circulating S100A8/A9 compared to responders and healthy controls, but without variations of S100A8 and S100A9 homodimers. In MDS patients, circulating S100A8 was significantly elevated compared to those of AA and/or healthy controls. By Pearson correlation analysis of protein levels and blood counts, multiple correlations were found. However, as S100A8 and S100A9 are abundantly present in white blood cells and platelets, correlations with blood counts likely mirror the higher number of cells in the blood of some patients. In conclusion, our findings indicate that circulating S100A8 is increased in MDS but not in AA, and that may be useful to distinguish these diseases in the differential diagnosis of bone marrow failure syndromes. Clinicaltrials.gov identifiers: NCT00260689, NCT00604201, NCT01328587, NCT01623167, NCT00001620, NCT00001397.

Keywords: Aplastic anemia; Bone marrow failure; Myelodysplastic syndromes; S100A8; S100A9.

Publication types

  • Clinical Trial
  • Research Support, N.I.H., Intramural

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Anemia, Aplastic / blood*
  • Anemia, Aplastic / diagnosis
  • Anemia, Aplastic / therapy
  • Calgranulin A / blood*
  • Calgranulin B / blood*
  • Child
  • Child, Preschool
  • Female
  • Humans
  • Immunosuppression
  • Male
  • Middle Aged
  • Myelodysplastic Syndromes / blood*
  • Myelodysplastic Syndromes / diagnosis
  • Myelodysplastic Syndromes / therapy

Substances

  • Calgranulin A
  • Calgranulin B
  • S100A8 protein, human
  • S100A9 protein, human

Supplementary concepts

  • Aplastic anemia, idiopathic

Associated data

  • ClinicalTrials.gov/NCT01328587
  • ClinicalTrials.gov/NCT01623167
  • ClinicalTrials.gov/NCT00001397
  • ClinicalTrials.gov/NCT00604201
  • ClinicalTrials.gov/NCT00001620
  • ClinicalTrials.gov/NCT00260689